Rapport Presents Phase 2 Data for Epilepsy Drug RAP-219
BOSTON & SAN DIEGO, USA — April 1, 2026 Rapport Therapeutics, Inc. announced that it will present new Phase...
epilepsy
Advertisement
Praxis Precision Medicines Gains FDA Priority Review Boost
BOSTON, March 30, 2026 Praxis Precision Medicines has achieved a major regulatory milestone as the U.S. Food and Drug...
Praxis Data Shows Breakthrough Seizure Control Across Epilepsies
BOSTON, MA — December 8, 2025 — Praxis Precision Medicines presented compelling new clinical results at the American Epilepsy...
Northwestern Scientists Develop Model to Predict Risk of Sudden Death in Epilepsy Patients
CHICAGO, IL – November 11, 2025 — Scientists at Northwestern University Feinberg School of Medicine have developed a novel...
NeuroSigma Study Reveals Real-Time Brain Effects of eTNS
Los Angeles, California – November 3, 2025 NeuroSigma, Inc., a Los Angeles-based bioelectronics company, has announced a groundbreaking publication...
Advertisement
